‹ÆÑW

‹ÆÑW

2012”N

‰¢•¶

˜a•¶Œ´’˜EÇ—á•ñ

˜a•¶‘à

’˜‘

Šw‰ï”­•\

Œ¤‹†•â•‹à

”ljï‹c•ñ

‚»‚Ì‘¼


‹ÆÑW–ÚŽŸ‚Ö

ŽóÜ—ð

‹ÆÑW

2012”N@‰¢•¶

Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaoka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki T, Ito H, Yoshikawa K, Yamawaki S, Suzuki S, Watanabe D, Hioki H, Kaneko T, Makioka K, Okamoto K, Takuma H, Tamaoka A, Hasegawa K, Nonaka T, Hasegawa M, Kawata A,Yoshida M, Nakahata T, Takahashi R, Marchetto MCN, Gage FH, Yamanaka S, Inoue (2012) Drug screening for ALS using patient-specific induced pluripotent stem cells. Science Translational Medicine 4:1-8

Furuta N, Ikeda M, Hirayanagi K, Fujita Y, Amanuma M, Okamoto K (2012) A novel GJA1 mutation in oculodentodigital dysplasia with progressive spastic paraplegia and sensory deficts. Intern Med 51; 93-98

Hashimoto Y, Muramatsu K, Kunii M, Yoshimura S, Yamada M, Sato T, Ishida Y, Harada R, Harada A (2012) Uncovering genes required for neuronal morphology by morphology-based gene trap screening with a revertible retrovirus vector. FASEB J 26; 4662-4674

Ikeda M, Hirayanagi K, Arai M, Kakuda S, Makioka K, Furuta N, Takai E, Kasahara H, Tsukagoshi S, Fujita Y, Amari M, Takatama M, Nakazato Y, Okamoto K. 2012)@Encephalopathy with amyloid angiopathy and numerous plaques in low levels of CSF AƒÀ1-40/AƒÀ1-42. Amyloid 19; 186-90

Ikeda Y, Ohta Y, Kobayashi H, Okamoto M, Takamatsu K, Ota T, Manabe Y, Okamoto K, Koizumi A, Abe K (2012) Clinical features of ACA36. A novel spinocerebellar ataxia with motor neuron involvement (Asidan). Neurology 79; 333-341

Makioka K, Yamazaki T, Takatama M, Nakazato Y, Okamoto K (2012) Activation and alteration of lysosomes in multiple system atrophy. Neuroreport 23; 270-276

Mizuno Y, Fujita Y, Takatama M, Okamoto K (2012) Comparison of phosphorylated TDP-43-positive inclusions in oculomotor neurons in patients with non-ALS and ALS disorders. J Neurol Sci 315; 20-25

Nawa M, Kage-Nakadai E, Aiso S, Okmaoto K, Mitani A, Matsuoka M (2012) The reduced Expression of BTBD10, an Akt Activator, is neurotoxic and possibly contributes to the ALS pathogenesis. Cell Death Differ 19; 1398-407

Sohmiya M, Wada N, Tazawa M, Okamoto K, Shirakura K (2012) Immediate effects of physical therapy on gait disturbance and@frontal assessment battery in Parkinsonfs disease. Geriatr Gerontol Int 13; 630-7

Ushikubo M, Okamoto K (2012) Circumstances surrounding death and nursing difficulties with end-of-life care for individuals with ALS in central Japan.Int J Palliat Nurs 18; 554-60

 

ƒy[ƒW‚̐擪‚Ö